- Home
- KNSL vs RVMD Comparison
KNSL vs RVMD Comparison
Compare KNSL & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSL | RVMD |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.5B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNSL | RVMD |
|---|---|---|
| Price | $390.71 | $79.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $483.78 | $77.11 |
| AVG Volume (30 Days) | 253.2K | ★ 2.2M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 16.09 | N/A |
| EPS | ★ 20.35 | N/A |
| Revenue | ★ $1,802,839,000.00 | N/A |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $7.74 | $714.50 |
| P/E Ratio | $19.25 | ★ N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $349.00 | $29.17 |
| 52 Week High | $521.13 | $81.49 |
Technical Indicators
Market Signals| Indicator | KNSL | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 74.32 |
| Support Level | $349.00 | $77.54 |
| Resistance Level | $401.15 | $80.44 |
| Average True Range (ATR) | 10.66 | 2.44 |
| MACD | 4.11 | -0.52 |
| Stochastic Oscillator | 81.05 | 72.95 |
Price Performance
Historical ComparisonAbout KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.